Clinical Trials Update

Featured Image Courtesy: Byondis Biopharmaceuticals (previously Synthon Biopharmaceuticals, Nijmegen, The Netherlands.

New Phase I Study Investigates [Vic-]Trastuzumab Duocarmazine + Niraparib in HER2-Expressing Solid Tumors

As part of a new study focusing on advanced targeting human epidermal growth factor receptor-2 (HER2-) expressing cancers, including...

Daiichi Sankyo and AstraZeneca to Jointly Evaluate Patritumab Deruxtecan + Osimertinib in EGFR-Mutated...

Earlier this week Daiichi Sankyo and AstraZeneca confirmed that the companies had entered into a clinical trial collaboration with...

CHMP Adopts Positive Opinion for Belantamab Mafodotin, Recommending Approval for the Treatment of R/R...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive...
Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

Daiichi Sankyo and Gustave Roussy Sign Multi-year and Multi-study Adaptive Phase II Trial Collaboration

Daiichi Sankyo and Gustave Roussy have signed a multi-year, multi-study research collaboration for the ongoing development of DS-1062 and patritumab...
Featured Image: Multiple microscopic slides with stained blood smears, ready for testing. Courtesy: © Fotolia. Used with permission.

First Patients Dosed with Combination of Loncastuximab Tesirine + Ibrutinib in DLBCL and MCL

Diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are two distinct subtypes of non-Hodgkin lymphoma (NHL). These...

First Patients Dosed in Phase II Trial with Trastuzumab Duocarmazine in HER2-expressing Endometrial Carcinoma

A first patient has started treatment in a Phase II study designed to evaluate the safety and efficacy of...
Featured Image Courtesy: Byondis Biopharmaceuticals (previously Synthon Biopharmaceuticals, Nijmegen, The Netherlands.

Trastuzumab Duocarmazine Selected to be part of a New Investigational Treatment Arm for the...

The Quantum Leap Healthcare Collaborative™, a 501c(3) charitable organization established as a collaboration between medical researchers at University of...

U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in...

San Francisco Bay Area-based Bolt Biotherapeutics confirmed that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent...

HER2-targeting Trastuzumab Deruxtecan Shows Promise in Patients with Non-breast/Gastric Cancers

Results from a phase I study investigating fam-trastuzumab deruxtecan-nxki (formerly known as DS-8201a; Enhertu®; Daiichi Sankyo and AstraZeneca) showed...
Featured Image: Genmab's bioreactor laboratory. Photo Courtesy: 2020 Genmab.

Positive Phase II Trial Results for Tisotumab Vedotin Cervical Cancer

The phase II innovaTV 204 trial, a single-arm clinical trial also known as GCT1015-04 or GOG-3023/ENGOT-cx6 (NCT03438396), evaluating tisotumab...

X